Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulocuplumab and Ibrutinib in CXCR4-Mutated Waldenstrom's Macroglobulinemia
NCT03225716Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2017
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ulocuplumab in Waldenström macroglobulinemia (WM) (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose of Ulocuplumab at 8 weeks. Started Oct 2017; status: terminated.
02
Drugs
ulocuplumab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT03225716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03225716.